We report a case of rapidly fatal Pseudomonas aeruginosa community-acquired pneumonia (CAP) in a previously healthy 67-year-old woman. Eleven published case reports of P. aeruginosa CAP in previously healthy adults are reviewed. According to our review, the mean age of affected patients is 45.3 years. Five patients described in the literature were smokers with a mean smoking history of 40 pack-years. The clinical presentation is nonspecific, and although the pneumonia can be rapidly fatal, only 33% of the patients who were reported died. However, mortality may be independent of treatment within the first 36 hours of presentation. Exposure to aerosols of contaminated water is a risk factor for P. aeruginosa CAP in this population. Pseudomonas CAP should be considered in the differential diagnosis for anyone with a smoking history who presents with rapidly progressive pneumonia. We discuss treatment recommendations that are based on evidence in the currently available literature on the subject.
We report a case of rapidly fatal Pseudomonas aeruginosa community-acquired pneumonia (CAP) in a previously healthy 67-year-old woman. Eleven published case reports of P. aeruginosa CAP in previously healthy adults are reviewed. According to our review, the mean age of affected patients is 45.3 years. Five patients described in the literature were smokers with a mean smoking history of 40 pack-years. The clinical presentation is nonspecific, and although the pneumonia can be rapidly fatal, only 33% of the patients who were reported died. However, mortality may be independent of treatment within the first 36 hours of presentation. Exposure to aerosols of contaminated water is a risk factor for P. aeruginosa CAP in this population. Pseudomonas CAP should be considered in the differential diagnosis for anyone with a smoking history who presents with rapidly progressive pneumonia. We discuss treatment recommendations that are based on evidence in the currently available literature on the subject.
Pseudomonas aeruginosa is a common nosocomial pathogen that often causes pneumonia in hospitalized patients. The majority of these patients have an underlying medical condition or a risk factor for Pseudomonas infection. Although rare, there have been case reports of previously healthy individuals with community-acquired pneumonia (CAP) caused by P. aeruginosa. Such cases are often rapidly progressive and may be fatal. In this case report, we describe rapidly progressive P. aeruginosa CAP in a previously healthy 67-year-old woman. The Englishlanguage medical literature was reviewed, and 11 other cases were identified. Both a review of these cases and treatment recommendations made on the basis of the currently available literature are presented.
Methods
The chart and histology slides of the patient with P. aeruginosa reported in the present study were reviewed, and to identify other cases of P. aeruginosa CAP that occurred in previously healthy individuals reported in the English-language literature since 1966, a MEDLINE search was performed with the use of the key words "Pseudomonas" and "pneumonia." "Healthy patients" were defined as patients who did not have any preexisting medical conditions, including lung disease, renal disease, malignancies, organ transplantation, or immunosuppression. Patients with P. aeruginosa pneumonia had to have clinical histories and radiographic findings consistent with pneumonia, and they had to have P. aeruginosa isolated from cultures of blood, lung tissue, or pleural fluid specimens. Sputum specimens with culture results positive for P. aeruginosa were accepted as the cause of the pneumonia if the organism was isolated in pure culture and if the Gram-stained section showed many polymorphonuclear leukocytes and gram-negative bacilli. Eleven publications describing a total of 13 cases were identified and reviewed [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . Ten publications with 11 case reports met the definitions outlined above. The authors of one publication that described 2 cases found CAP with Pseudomonas species isolated from sputum samples, but there was no mention of whether gramnegative bacilli were seen [11] . Treatment of Pseudomonas pneumonia was also reviewed by use of the same format, and summary recommendations were made on the basis of the evidence in the literature.
Case Report
A 67-year-old woman who was employed as a secretary was assessed in the emergency department on 9 February 1996 for a 7-day history of diarrhea, a 4-day history of nonproductive cough, and a 24-h history of pleuritic chest pain. She had been healthy previously, but she was a smoker with a 30 pack-year history. She denied having any history of fever or chills. Physical examination indicated a temperature of 37.4ЊC and a blood pressure of 110/60 mm Hg with a mild orthostatic decrease. Her respiratory rate was 28 breaths/min. Examination of her chest revealed crackles at the bases of both lungs, with rhonchi present in both upper lobes. Crusted linear lacerations were noted on her right lower leg. Examination of a chest radiograph indicated bilateral opacities consistent with bronchopneumonia (figure 1). The patient had hypoxia with a partial pressure of oxygen of 60 mm Hg and an oxygen saturation of 89% while breathing room air. Her initial WBC count was cells/ L. Although the patient did not have a known history of diabetes, she was found to have a significant anion gap acidosis and elevated serum levels of glucose (24.6 mM) and ketones (5 mM) suggestive of diabetic ketoacidosis. Treatment of CAP with cefuroxime and erythromycin was begun, and she was admitted to the general medicine service at 10:00 P.M. During the next day, the patient's condition deteriorated, her dyspnea worsened, and she experienced respiratory distress and metabolic acidosis. Twenty-four hours after admission to the hospital, she was transferred to the intensive care unit (ICU), where she underwent intubation for worsening hypoxia and respiratory distress. Chest examination revealed bilateral bronchial breath sounds at the bases of her lungs, and analysis of another chest radiograph indicated an increase in pulmonary opacities, a finding that is consistent with a rapidly progressive bronchopneumonia with infiltrates in the right upper and left mid-and lower lung fields (figures 2, 3, 4, and 5). The antibiotic treatment was changed to ceftriaxone, erythromycin, and rifampin; this was later changed to ciprofloxacin, erythromycin, and rifampin. The patient developed neutropenia (absolute neutrophil count, cells/L) and septic shock with profound 9 0.9 ϫ 10 hypotension refractory to maximum doses of inotropic medication. She died at 11:40 A.M. on 11 February (36 h after admission).
The results of cultures of blood samples obtained at the time of the patient's admission to the hospital remained negative. However, cultures of blood and endotracheal secretions obtained at the time she was transferred to the ICU yielded P. aeruginosa. Autopsy revealed extensive bilateral bronchopneumonia with abscess formation and necrosis of the alveolar walls in all lobes of the lung. In addition, there was significant perivascular inflammation, and Gram-stain preparations revealed gram-negative rods suggestive of P. aeruginosa (figures 6, 7, and 8).
Literature Review
Although CAP secondary to P. aeruginosa is rare, our review of the literature on the subject indicated that it can affect healthy individuals and that it can be fatal (tables 1 and 2). Patients tend to be middle-aged (mean age ‫ע‬ SD, 45 ‫ע‬ 15 years), and 5 patients discussed in the literature were smokers (mean history of smoking ‫ע‬ SD, pack-years). Pre-40 ‫ע‬ 18.3 sentation may be variable, with cough, pleuritic chest pain, fever, and sputum production present in 150% of the patients reported. Of those who had sputum production, 50% had hemoptysis. The mean WBC count ‫ע‬ SD was 9 2.5 ‫ע‬ 7.75 ϫ 10 cells/L. Any lobe of the lung can be involved, but two-thirds of the patients experience involvement of the right upper lobe. Six (54.5%) of 11 patients had hypotension, and 67% had hypoxemia at the time of admission. Seventy-five percent required intubation within 48 h of admission. Six of 11 patients had gram-negative rods in the sputum samples that were taken at the time of presentation [2, 3, 5, 6, 8, 10] . Two more patients could not produce any sputum at the time of initial presentation [9, 4] ; however, 8 h after admission, 1 of these patients produced a sputum sample that also had gram-negative rods [4] . More than 92% of patients had bacteremia, and 83% had P. aeruginosa isolated from sputum specimens. Although the mortality rate in this series was only 33%, death occurred quickly, with a median time of 11 h from admission to death. Of those who survived, at the time of admission, only 1 person was treated empirically with an antibiotic effective against Pseudomonas species. For the remaining survivors, therapy was directed by positive culture results 1-3 days after admission. For those who survived, the mean hospital stay ‫ע‬ SD was days. 29 ‫ע‬ 12.6
Discussion
Rare cases of CAP due to P. aeruginosa have been documented since the 1960s. Pseudomonas infection is a poor prognostic indicator of mortality in patients with CAP (OR, 51.4), with the majority of cases involving patients with underlying disease, including malignancy, cystic fibrosis, aplastic anemia, and bronchiectasis [12] [13] [14] . During a 3-year prospective study of 127 patients with pneumonia who required admission to the ICU, 58 of the cases (45.7%) were community acquired, with P. aeruginosa noted as the third most common microorganism etiology (after Legionella species and pneumococcus) [15] . P. aeruginosa was second to S. pneumoniae as the most common causal agent in CAP that required ICU admission in Saudi Arabia. Seventy-eight percent of these patients were also found to have coexisting disease [16] . In a meta-analysis of 33,148 patients with CAP in 127 study cohorts, Fine et al. [14] identified 18 patients with P. aeruginosa pneumonia and a mortality rate of 61.1% (11 of 18 patients). We do not know how many of these patients previously were healthy.
P. aeruginosa CAP in previously healthy patients is rare, but there have been 11 cases documented since 1968 (table 2). Rose [17] reported the development of chronic pneumonia due to P. aeruginosa in a 43-year-old man. Although the patient was considered to be previously healthy, investigations made while he was in the hospital indicated evidence of chronic obstructive lung disease. Vikram et al. [11] reported 2 cases of Pseudomonas CAP; the patients each presented with a subacute illness with respiratory symptoms, weight loss, and malaise. These patients did not have bacteremia and did not have any gram-negative organisms identified on the Gram stain of their sputum samples; however, cultures of sputum samples from these patients yielded P. aeruginosa, which suggests that it was the cause of their pneumonia. This presentation is similar to that of P. aeruginosa CAP in patients with HIV [18] .
In contrast, there have been other reports of rapidly progressive and fatal cases of P. aeruginosa pneumonia similar to that observed in the patient in the present study. Henderson et al. [8] described 2 cases of primary P. aeruginosa pneumonia that resulted in death within 36 h, and Govan et al. [2] reported a case of a previously healthy 49-year-old man who died within 12 h of being admitted to the hospital. P. aeruginosa was subsequently isolated both from sputum and blood samples that had been taken at the time of admission as well as from samples from postmortem specimens of his lung, liver, and spleen. Although a necrotizing vasculitis has typically been described in immunocompromised patients with Pseudomonas infection [19] , the patient described in the present study and 2 of the 3 patients who are described in the literature on the subject and who died had evidence of gram-negative bacilli invading the walls of alveolar blood vessels (the third patient had gram-negative bacilli in the pulmonary interstitium) [2, 8] . However, not all cases of Pseudomonas pneumonia result in death. Since 1971, there have been 8 published case reports of previously healthy men and women who survived Pseudomonas pneumonia as a result of receiving appropriate antibiotic treatment. Although they did not have any underlying medical conditions, 5 of the patients smoked tobacco [1-3, 7, 10] .
Henderson et al. [8] suggested that P. aeruginosa CAP should be suspected in any patient who has environmental risk factors and has gram-negative bacilli seen on the Gram stain of the sputum sample, and who presents with pneumonia with overwhelming sepsis. P. aeruginosa pneumonia has been associated with exposure to contaminated aerosolized water. Harris et al. [6] reported a case of P. aeruginosa pneumonia in a patient with chronic asthma who had been using a home humidifying device that contained water contaminated with P. aeruginosa. There was no indication of recent exposure to corticosteroids, antibiotic use, or other risk factors associated with Pseudomonas infection. Home whirlpool spas have also been implicated as a cause of P. aeruginosa pneumonia in previously healthy patients. Rose et al. [5] reported the case of a patient who was exposed to aerosolized water for 90 min while in a whirlpool. P. aeruginosa was later isolated from the water in the whirlpool as well as from the aerosolized mist generated by the spa. Rose et al. [5] proposed that the patient most likely became infected after inhaling the aerosolized contaminated water. Occupational exposure may also be a risk factor for Pseudomonas pneumonia. Cirigliano and Grippi [9] published a case report of Pseudomonas pneumonia in a previously healthy nursing assistant. They suggest that she may have been colonized by microorganisms and that she subsequently developed an infection as a result of occupational exposure to Pseudomonas species. Exposure to dusts containing such metals as iron has been an associated risk factor for Acinetobacter CAP [20] . The patients described in the literature that we reviewed included a welder and a foundry worker, both of whom were probably exposed to dust containing metals such as iron [2, 3] .
The treatment of P. aeruginosa pneumonia can be difficult because this microorganism tends to be resistant to the usual antibiotics recommended for the treatment of CAP. In the report by Torres et al. [13] , all 5 patients who presented with severe CAP due to P. aeruginosa had bronchiectasis; this suggests that patients with structural lung disease should receive broader therapy. Both the American Thoracic Society and Canadian guidelines for treatment of CAP recommend that patients with structural lung disease who present with CAP should be given antibiotics that are effective against P. aeruginosa [21, 22] .
There have been no randomized clinical trials of the treatment of P. aeruginosa pneumonia; therefore, we have extra- polated treatment recommendations from trials that examined the treatment of Pseudomonas bacteremia. There are a number of appropriate choices of anti-Pseudomonas antibiotics, including imipenem-cilastatin, meropenem, piperacillin-tazobactam, ticarcillin-clavulanate, and ciprofloxacin, or an appropriate third-generation cephalosporin, such as ceftazidime [23, 24] . Whether to use monotherapy or combination therapy remains controversial, and to our knowledge, no randomized controlled trials have been conducted to examine this question. By use of a guinea pig model of Pseudomonas pneumonia, Pennington and Stone [25] and Pennington et al. [26] demonstrated that the combination of tobramycin and a b-lactam did not produce any greater effects on survival when compared with monotherapy with tobramycin. However, when the animals developed neutropenia as a result of pretreatment with cyclophosphamide, survival was significantly higher among animals treated with the combination of ticarcillin, ceftazidime, or azlocillin with tobramycin than it was among those treated with single-drug therapy [27] .
In addition, the use of monotherapy with antipseudomonal penicillins or cephalosporins for patients with severe Pseudomonas infections can lead to the emergence of antimicrobialresistant stains [24] . The combination of 2 antipseudomonal blactam antibiotics lacks synergy in animal models; similar findings have been found regarding infections in humans [24, 28] . Analysis of in vitro data suggests that the combination of an aminoglycoside and a b-lactam antibiotic works synergistically against P. aeruginosa [27, 29] , and improved clinical outcomes have been observed when this combination is used to treat serious P. aeruginosa infections. Leibovici et al. [30] evaluated 346 cases of P. aeruginosa bacteremia during a prospective observational study that compared the use of the b-lactamaminoglycoside combination with the use of monotherapy for the treatment of 2165 patients with gram-negative bacteremia. There was no overall difference in mortality rates; however, subgroup analysis revealed a trend toward improved mortality in patients with Pseudomonas bacteremia who received combination therapy.
In a prospective observational study, Hilf et al. [29] analyzed 200 consecutive cases of Pseudomonas bacteremia and found that 28 (15%) of 186 of these patients had pneumonia as the source of the bacteremia. There was an overall statistically significant reduction in mortality in the group that received combination therapy (aminoglycoside and a b-lactam), compared with those who received monotherapy (32% vs. 51%). Siegman-Igra et al. [31] argued that, in the Hilf study, the majority of patients who received monotherapy were treated with aminoglycosides alone, which they considered "inappropriate" antibiotic coverage. In their retrospective review, SiegmanIgra et al. [31] found that there was no significant difference in infection-related mortality between patients treated with monotherapy (consisting of an anti-Pseudomonas cephalosporin, a quinolone, or imipenem-cilastatin) and those treated with combination therapy (the aforementioned drugs plus an aminoglycoside) (14% vs. 13%, respectively).
The use of aminoglycosides for the treatment of Pseudomonas pneumonia is also controversial. By use of a nonneutropenic guinea pig model of P. aeruginosa pneumonia, Pennington and Stone [25] and Pennington et al. [26] showed that animals treated with tobramycin monotherapy had significantly higher survival rates and greater clearance of P. aeruginosa from the lungs than did those treated with monotherapy with antipseudomonal penicillins and cephalosporins. However, the antibacterial activity of aminoglycosides against the microorganism(s) causing the pneumonia is limited by poor penetration into the lung tissue (although some data suggest that this can be overcome by adequate serum levels), the acidic environment of the lung, and the presence of inflammatory cells [32, 33] . The poor pharmacokinetics, inconsistent clinical data, and toxicity make parenteral aminoglycosides a less-than-ideal choice for the treatment of pneumonia. Endotracheal administration of tobramycin has been associated with improved clearance of P. aeruginosa from the sputum; however, no difference in clinical outcome could be demonstrated [34] . Intermittent administration of inhaled tobramycin recently has been shown to be effective in improving pulmonary function and decreasing the risk of hospitalization among patients with cystic fibrosis [35] . This treatment was able to reduce the density of P. aeruginosa in the sputum of these patients; however, MICs for tobramycin increased during the study period, suggesting that the development of resistance is a potential problem [35] . Ciprofloxacin is the most effective fluoroquinolone against P. aeruginosa, and it is effective for the treatment of Pseudomonas pneumonia in animal models [36, 37] . In vitro data regarding synergism seen with the combination of ciprofloxacin and other antibiotics are variable [38] . Bustamante et al. [39] demonstrated that synergy with a combination of ciprofloxacin and either aztreonam or azlocillin depended on whether the isolate was resistant to the b-lactam antibiotic. When the isolates were resistant to b-lactams, synergy was achieved in !10% of isolates, compared with success in 150% of isolates when the isolate was susceptible to these agents but was resistant to ciprofloxacin. The combination of ciprofloxacin and ceftazidime achieved in vitro synergy in 75% of the isolates tested. The combination of trovafloxacin with other antibiotics, including ceftazidime, amikacin, and imipenem, is additive rather than synergistic [37] .
Analysis of other data has shown that the various quinolonepenicillin or quinolone-cephalosporin combinations are indifferent [36] . There have been no examples of antagonism with any of these combinations, and the results of animal studies suggest that ciprofloxacin-b-lactam combinations are efficacious [38, 40] . The combination of ciprofloxacin and azlocillin was as effective as that of amikacin and azlocillin, and it was more effective than amikacin and ciprofloxacin used in vivo for the treatment of P. aeruginosa infection in the rabbit chamber model [40] . In vitro data used to examine aminoglycoside-quinolone combinations also show variation, with some isolates demonstrating synergism and others showing indifference and, in some cases, antagonism [38, 41] . There is also in vitro evidence of synergy when ciprofloxacin is combined with vancomycin [42] . However, to our knowledge, there are no data to examine the effectiveness of these combination in humans. Despite the paucity of evidence for synergism between fluoroquinolones and other antibiotics, the fact that they affect different targets within the microorganism means, theoretically, that they could reduce the chance of the development of resistance.
The current guidelines from the Infectious Diseases Society of America suggest that patients with CAP who are hospitalized in the ICU should receive a macrolide or a fluoroquinolone plus cefotaxime or ceftriaxone or a b-lactam-b-lactamase inhibitor. Patients with structural lung disease, such as bronchiectasis, should receive broader therapy with such antipseudomonal agents as (1) an antipseudomonal penicillin, carbapenem, or cefepime plus a macrolide, or (2) a fluoroquinolone plus an aminoglycoside [43] . Only 1 of the patients reviewed in the present study received empiric antibiotic therapy that was effective against P. aeruginosa [10] . The remaining patients who survived had their initial therapeutic regimen changed to one that contained antibiotics effective against P. aeruginosa after the patients showed clinical deterioration or had microbial evidence of a Pseudomonas infection. (All of those who produced sputum samples had gram-negative bacilli on Gram stain.) The time for this change was 1-3 days (table 2) [3] [4] [5] [6] [7] 9] . In the present study, although the 4 patients who died of their infections received empiric therapy that would be ineffective against P. aeruginosa, the median time to death was 11 h [2, 8] . This suggests that mortality within the first 36 h may be independent of whether empiric therapy included an antibiotic effective against P. aeruginosa.
Until the issue of monotherapy versus combination therapy is resolved with appropriate clinical trials, the following ap- proaches could be adopted for the treatment of patients with risk factors for Pseudomonas infection:
1. Intravenous ceftazidime (1 g given every 6 h) plus iv ciprofloxacin (400 mg given every 12 h); or iv imipenem-cilastatin (500 mg given every 6 h). 2. Intravenous imipenem-cilastatin (500 mg given every 6 h) or iv meropenem (1 g given every 8 h) plus iv ciprofloxacin (400 mg given every 12 h). 3. Intravenous piperacillin (3 g given every 6 h) or iv ticarcillin (3 g given every 4 h) plus iv ciprofloxacin (400 mg given every 12 h) or iv imipenem-cilastatin (500 mg given every 6 h) or iv meropenem (1 g given every 8 h).
Ciprofloxacin, imipenem-cilastatin, ceftazidime, or meropenem all may be appropriate choices for monotherapy of P. aeruginosa pneumonia, although the possibility of emergence of resistance during therapy must be kept in mind.
Conclusions
Although it is rare, P. aeruginosa CAP is often rapidly progressive and can occur in previously healthy patients with a 33% mortality rate. Risk factors, such as exposure to aerosols of contaminated water, may be easily overlooked; the history of such exposures should be carefully assessed in each patient presenting with severe CAP. P. aeruginosa must be considered in the differential diagnosis for anyone presenting with a rapidly progressive pneumonia, particularly in patients with a history of smoking; gram-negative bacilli in the sputum should raise clinical diagnostic suspicion. Treatment should consist of combination therapy with anti-Pseudomonas agents to prevent the emergence of resistance.
